what is clindamycin hcl 300 mg used to treat

What is Clindam (clindamycin) and how is it used?

Clindam (clindamycin) is a prescription antibody medication used to care for serious infections caused by anaerobic leaner. Clindamycin may be used alone or with other medications.

Clindam (clindamycin) is an antibiotic, lincosamide drug class.

What are the possible side furnishings of Clindam (clindamycin)?

Clindam (clindamycin) may cause serious side effects including:

• any changes in bowel habits,
• severe stomach pain,
• diarrhea that is watery or bloody,
• little or no urination, and
• metal taste in your rima oris (subsequently injecting Clindamycin)

Get medical help correct away, if y'all have any of the symptoms listed higher up.

The about common side effects of Clindam (clindamycin) include:

• nausea,
• vomiting,
• tum pain,
• mild skin rash, and
• vaginal itching or discharge

Get medical help right away, if you take any of the symptoms listed higher up.

These are non all the possible side effects of Clindamycin. For more information, ask your dr. or chemist.

Call your doc for medical communication near side effects. Yous may study side effects to FDA at one-800-FDA-1088.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLEOCIN HCl and other antibacterial drugs, CLEOCIN HCl should be used just to care for or prevent infections that are proven or strongly suspected to be caused by bacteria.

WARNING

Clostridium difficile associated diarrhea (CDAD) has been reported with the apply of about all antibacterial agents, including CLEOCIN HCl and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficle.

Because CLEOCIN HCl therapy has been associated with astringent colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the INDICATIONS AND USAGE section. Information technology should non be used in patients with nonbacterial infections such equally most upper respiratory tract infections.

C. difficile produces toxins A and B, which contribute to the evolution of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea post-obit antibiotic use. Conscientious medical history is necessary since CDAD has been reported to occur over two months afterward the assistants of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use non directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte direction, protein supplementation, antibody treatment of C. difficile, and surgical evaluation should exist instituted as clinically indicated.

Clarification

Clindamycin hydrochloride is the hydrated hydrochloride table salt of clindamycin. Clindamycin is a semisynthetic antibiotic produced past a 7(South)-chloro-substitution of the vii(R)-hydroxyl group of the parent compound lincomycin.

CLEOCIN HCl Capsules contain clindamycin hydrochloride equivalent to 75 mg, 150 mg, or 300 mg of clindamycin.

Inactive ingredients:

• 75 mg - corn starch, FD&C blue no. one, FD&C yellowish no. 5, gelatin, lactose, magnesium stearate, and talc;
• 150 mg - corn starch, FD&C blue no. 1, FD&C yellowish no. 5, gelatin, lactose, magnesium stearate, talc and titanium dioxide;
• 300 mg - corn starch, FD&C bluish no. ane, gelatin, lactose, magnesium stearate, talc, and titanium dioxide.

The structural formula is represented beneath:

The chemic proper noun for clindamycin hydrochloride is Methyl 7-chloro-6,7,eight-trideoxy-6­(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto  ­octopyranoside monohydrochloride.

3 pharmacies near 11430 have coupons for clindamycin (Brand Names:Cleocin for 150MG)

INDICATIONS

Clindamycin is indicated in the treatment of serious infections acquired past susceptible anaerobic bacteria.

Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its employ should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the medico, a penicillin is inappropriate. Because of the take chances of colitis, every bit described in the BOXED Alarm, before selecting clindamycin, the doctor should consider the nature of the infection and the suitability of less toxic alternatives (eastward.g., erythromycin).

Anaerobes

Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra­abdominal infections such every bit peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal alimentary canal); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection.

Streptococci

Serious respiratory tract infections; serious pare and soft tissue infections.

Staphylococci

Serious respiratory tract infections; serious pare and soft tissue infections.

Pneumococci

Serious respiratory tract infections.

Bacteriologic studies should be performed to make up one's mind the causative organisms and their susceptibility to clindamycin.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLEOCIN HCl and other antibacterial drugs, CLEOCIN HCl should exist used only to treat or forbid infections that are proven or strongly suspected to be caused past susceptible bacteria. When culture and susceptibility information are bachelor, they should exist considered in selecting or modifying antibacterial therapy. In the absenteeism of such data, local epidemiology and susceptibility patterns may contribute to the empiric pick of therapy.

QUESTION

Bowel regularity means a bowel motion every day. See Respond

DOSAGE AND Assistants

If significant diarrhea occurs during therapy, this antibiotic should exist discontinued (meet BOXED WARNING).

Adults:

• Serious infections - 150 to 300 mg every 6 hours.
• More than severe infections - 300 to 450 mg every 6 hours.

Pediatric Patients:

• Serious infections - 8 to xvi mg/kg/day (4 to eight mg/lb/day) divided into 3 or four equal doses.
• More than severe infections - 16 to twenty mg/kg/day (8 to ten mg/lb/day) divided into three or 4 equal doses.

To avoid the possibility of esophageal irritation, CLEOCIN HCl Capsules should be taken with a full glass of h2o.

Serious infections due to anaerobic bacteria are ordinarily treated with CLEOCIN PHOSPHATE® Sterile Solution. Withal, in clinically appropriate circumstances, the physician may elect to initiate handling or go along treatment with CLEOCIN HCl Capsules.

In cases of β-hemolytic streptococcal infections, treatment should continue for at least 10 days.

HOW SUPPLIED

CLEOCIN HCl Capsules are available in the following strengths, colors and sizes:

• 75 mg Light-green

Bottles of 100 NDC 0009-0331-02

• 150 mg Calorie-free Blue and Greenish

Bottles of 100 NDC 0009-0225-02
Unit dose package of 100 NDC 0009-0225-03

• 300 mg Light Bluish

Bottles of 100 NDC 0009-0395-xiv
Unit dose package of 100 NDC 0009-0395-02

Store at controlled room temperature xx° to 25° C (68° to 77° F) [come across USP].

Distributed by; Pharmacia & Upjohn Co, Division of Pfizer Inc., NY, NY 10017. Revised July 2016

Side Effects & Drug Interactions

SIDE Furnishings

The following reactions have been reported with the utilize of clindamycin.

Infections and Infestations: Clostridium difficile colitis

Gastrointestinal: Abdominal pain, pseudomembranous colitis, esophagitis, nausea, vomiting, and diarrhea (encounter BOXED WARNING). The onset of pseudomembranous colitis symptoms may occur during or subsequently antibacterial treatment (run across WARNINGS). Esophageal ulcer has been reported. An unpleasant or metallic taste has been reported after oral administration.

Hypersensitivity Reactions: Generalized mild to moderate morbilliform-similar (maculopapular) skin rashes are the most frequently reported agin reactions. Vesiculobullous rashes, as well as urticaria, have been observed during drug therapy. Astringent skin reactions such every bit Toxic Epidermal Necrolysis, some with fatal outcome, have been reported (Meet WARNINGS). Cases of Acute Generalized Exanthematous Pustulosis (AGEP), erythema multiforme, some resembling Stevens-Johnson syndrome, anaphylactic shock, anaphylactic reaction and hypersensitivity accept also been reported.

Skin and Mucous Membranes: Pruritus, vaginitis, angioedema and rare instances of exfoliative dermatitis have been reported. (See Hypersensitivity Reactions.)

Liver: Jaundice and abnormalities in liver part tests take been observed during clindamycin therapy.

Renal: Although no directly relationship of clindamycin to renal damage has been established, renal dysfunction as evidenced by azotemia, oliguria, and/or proteinuria has been observed.

Hematopoietic: Transient neutropenia (leukopenia) and eosinophilia have been reported. Reports of agranulocytosis and thrombocytopenia take been made. No direct etiologic relationship to concurrent clindamycin therapy could be made in any of the foregoing.

Immune Organization: Drug reaction with eosinophilia and systemic symptoms (Wearing apparel) cases accept been reported.

Musculoskeletal: Cases of polyarthritis have been reported.

DRUG INTERACTIONS

Clindamycin has been shown to have neuromuscular blocking properties that may heighten the action of other neuromuscular blocking agents. Therefore, information technology should exist used with caution in patients receiving such agents.

Antagonism has been demonstrated betwixt clindamycin and erythromycin in vitro. Considering of possible clinical significance, these two drugs should non be administered meantime.

SLIDESHOW

Fungal Pare Infections: Types, Symptoms, and Treatments See Slideshow

WARNINGS

See BOXED WARNING

Clostridium Difficile Associated Diarrhea

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including CLEOCIN HCl, and may range in severity from mild diarrhea to fatal colitis. Handling with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile.

C. difficile produces toxins A and B, which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can exist refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic utilise. Careful medical history is necessary since CDAD has been reported to occur over two months afterward the assistants of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibody use non directed against C. difficile may need to exist discontinued. Appropriate fluid and electrolyte direction, poly peptide supplementation, antibiotic treatment of C. difficile, and surgical evaluation should exist instituted as clinically indicated.

Anaphylactic And Severe Hypersensitivity Reactions

Anaphylactic shock and anaphylactic reactions have been reported (see Agin REACTIONS).

Severe hypersensitivity reactions, including severe peel reactions such equally toxic epidermal necrolysis (10), drug reaction with eosinophilia and systemic symptoms (DRESS), and Stevens-Johnson syndrome (SJS), some with fatal upshot, take been reported (see Agin REACTIONS).

In case of such an anaphylactic or severe hypersensitivity reaction, discontinue handling permanently and institute appropriate therapy.

A careful inquiry should be fabricated concerning previous sensitivities to drugs and other allergens.

Usage In Meningitis

Since clindamycin does not diffuse adequately into the cerebrospinal fluid, the drug should not be used in the handling of meningitis.

PRECAUTIONS

General

Review of experience to engagement suggests that a subgroup of older patients with associated severe affliction may tolerate diarrhea less well. When clindamycin is indicated in these patients, they should be carefully monitored for change in bowel frequency.

CLEOCIN HCl should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.

CLEOCIN HCl should be prescribed with circumspection in atopic individuals.

Indicated surgical procedures should be performed in conjunction with antibody therapy.

The use of CLEOCIN HCl occasionally results in overgrowth of nonsusceptible organisms—peculiarly yeasts. Should superinfections occur, advisable measures should be taken as indicated by the clinical situation.

Clindamycin dosage modification may not be necessary in patients with renal disease. In patients with moderate to severe liver illness, prolongation of clindamycin half-life has been plant. However, information technology was postulated from studies that when given every eight hours, accumulation should rarely occur. Therefore, dosage modification in patients with liver disease may non exist necessary. All the same, periodic liver enzyme determinations should be fabricated when treating patients with severe liver disease.

The 75 mg and 150 mg capsules incorporate FD&C yellowish no. 5 (tartrazine), which may cause allergic-blazon reactions (including bronchial asthma) in certain susceptible individuals. Although the overall incidence of FD&C yellow no. v (tartrazine) sensitivity in the general population is low, information technology is frequently seen in patients who also take aspirin hypersensitivity.

Prescribing CLEOCIN HCl in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the run a risk of the evolution of drug-resistant bacteria.

Laboratory Tests

During prolonged therapy, periodic liver and kidney function tests and claret counts should be performed.

Carcinogenesis, Mutagenesis, Impairment Of Fertility

Long-term studies in animals have not been performed with clindamycin to evaluate carcinogenic potential. Genotoxicity tests performed included a rat micronucleus exam and an Ames Salmonella reversion examination. Both tests were negative.

Fertility studies in rats treated orally with up to 300 mg/kg/twenty-four hours (approximately 1.6 times the highest recommended adult human dose based on mg/g²) revealed no furnishings on fertility or mating ability.

Pregnancy

Teratogenic Effects

Pregnancy Category B

In clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters, has not been associated with an increased frequency of built abnormalities.

Clindamycin should be used during the first trimester of pregnancy only if clearly needed. There are no adequate and well-controlled studies in pregnant women during the first trimester of pregnancy. Considering animal reproduction studies are not always predictive of the human response, this drug should be used during pregnancy simply if conspicuously needed.

Reproduction studies performed in rats and mice using oral doses of clindamycin up to 600 mg/kg/day (3.2 and 1.half dozen times the highest recommended adult human dose based on mg/one thousand², respectively) or subcutaneous doses of clindamycin upwards to 250 mg/kg/solar day (one.3 and 0.7 times the highest recommended adult human dose based on mg/chiliad², respectively) revealed no evidence of teratogenicity.

Nursing Mothers

Clindamycin has been reported to appear in chest milk in the range of 0.7 to 3.eight mcg/mL. Because of the potential for serious adverse reactions in nursing infants, clindamycin should not exist taken past nursing mothers.

Pediatric Utilize

When CLEOCIN HCl is administered to the pediatric population (nativity to 16 years), appropriate monitoring of organ system functions is desirable.

Geriatric Use

Clinical studies of clindamycin did not include sufficient numbers of patients age 65 and over to make up one's mind whether they respond differently from younger patients. However, other reported clinical experience indicates that antibiotic-associated colitis and diarrhea (due to Clostridium difficile) seen in association with most antibiotics occur more oft in the elderly ( > 60 years) and may be more severe. These patients should be carefully monitored for the development of diarrhea.

Pharmacokinetic studies with clindamycin have shown no clinically important differences betwixt immature and elderly subjects with normal hepatic part and normal (age-adjusted) renal office after oral or intravenous administration.

Overdosage & Contraindications

OVERDOSE

Significant bloodshed was observed in mice at an intravenous dose of 855 mg/kg and in rats at an oral or subcutaneous dose of approximately 2618 mg/kg. In the mice, convulsions and low were observed.

Hemodialysis and peritoneal dialysis are non effective in removing clindamycin from the serum.

CONTRAINDICATIONS

CLEOCIN HCl is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

CLINICAL PHARMACOLOGY

Human Pharmacology

Absorption

Serum level studies with a 150 mg oral dose of clindamycin hydrochloride in 24 normal developed volunteers showed that clindamycin was chop-chop absorbed after oral administration. An average peak serum level of two.50 mcg/mL was reached in 45 minutes; serum levels averaged 1.51 mcg/mL at 3 hours and 0.70 mcg/mL at 6 hours. Absorption of an oral dose is virtually complete (xc%), and the concomitant administration of food does non appreciably modify the serum concentrations; serum levels accept been uniform and predictable from person to person and dose to dose. Serum level studies post-obit multiple doses of CLEOCIN HCl for upward to 14 days show no bear witness of accumulation or altered metabolism of drug. Doses of upward to ii grams of clindamycin per mean solar day for 14 days have been well tolerated by salubrious volunteers, except that the incidence of gastrointestinal side effects is greater with the higher doses.

Distribution

Concentrations of clindamycin in the serum increased linearly with increased dose. Serum levels exceed the MIC (minimum inhibitory concentration) for most indicated organisms for at least half dozen hours post-obit administration of the usually recommended doses. Clindamycin is widely distributed in trunk fluids and tissues (including bones). No significant levels of clindamycin are attained in the cerebrospinal fluid, even in the presence of inflamed meninges.

Excretion

The average biological one-half-life is ii.four hours. Approximately 10% of the bioactivity is excreted in the urine and 3.6% in the feces; the remainder is excreted every bit bioinactive metabolites.

Special Populations

Renal Harm

Serum half-life of clindamycin is increased slightly in patients with markedly reduced renal role. Hemodialysis and peritoneal dialysis are not effective in removing clindamycin from the serum.

Use in Elderly

Pharmacokinetic studies in elderly volunteers (61-79 years) and younger adults (18-39 years) indicate that age lone does not change clindamycin pharmacokinetics (clearance, elimination half-life, volume of distribution, and area under the serum concentration-time curve) after Iv administration of clindamycin phosphate. After oral assistants of clindamycin hydrochloride, elimination one-half-life is increased to approximately iv.0 hours (range iii.4-5.1 h) in the elderly compared to 3.2 hours (range 2.one - iv.2 h) in younger adults. The extent of absorption, however, is not different between age groups and no dosage alteration is necessary for the elderly with normal hepatic function and normal (age-adjusted) renal role¹.

Microbiology

Machinery of Action

Clindamycin inhibits bacterial protein synthesis past binding to the 23S RNA of the 50S subunit of the ribosome. Clindamycin is bacteriostatic.

Resistance

Resistance to clindamycin is about often caused by modification of specific bases of the 23S ribosomal RNA. Cross-resistance between clindamycin and lincomycin is consummate. Because the binding sites for these antibacterial drugs overlap, cantankerous-resistance is sometimes observed among lincosamides, macrolides and streptogramin B. Macrolide-inducible resistance to clindamycin occurs in some isolates of macrolide-resistant leaner. Macrolide-resistant isolates of staphylococci and beta-hemolytic streptococci should exist screened for consecration of clindamycin resistance using the D-zone test.

Antimicrobial Activity

Clindamycin has been shown to be agile against almost of the isolates of the following microorganisms, both in vitro and in clinical infections, equally described in the INDICATIONS AND USAGE department.

Gram-positive Bacteria

Staphylococcus aureus (methicillin-susceptible strains)
Streptococcus pneumoniae (penicillin-susceptible strains)
Streptococcus pyogenes

Anaerobic Bacteria

Clostridium perfringens
Fusobacterium necrophorum
Fusobacterium nucleatum
Peptostreptococcus anaerobius
Prevotella melaninogenica

At least 90% of the microorganisms listed below exhibit in vitro minimum inhibitory concentrations (MICs) less than or equal to the clindamycin susceptible MIC breakpoint for organisms of a similar type to those shown in Table one. However, the efficacy of clindamycin in treating clinical infections due to these microorganisms has not been established in adequate and well-controlled clinical trials.

Gram-positive Leaner

Staphylococcus epidermidis (methicillin-susceptible strains)
Streptococcus agalactiae
Streptococcus anginosus
Streptococcus mitis
Streptococcus oralis

Anaerobic Bacteria

Actinomyces israelii
Clostridium clostridioforme
Eggerthella lenta
Finegoldia (Peptostreptococcus) magna
Micromonas (Peptostreptococcus) micros
Prevotella bivia
Prevotella intermedia
Propionibacterium acnes

Susceptibility Testing Methods

When available, the clinical microbiology laboratory should provide cumulative in vitro susceptibility test results for antimicrobial drugs used in local hospitals and exercise areas to the md as periodic reports that describe the susceptibility profile of nosocomial and customs-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug for treatment.

Dilution Techniques

Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should exist determined using a standardized test method^2,3 (broth and/or agar). The MIC values should be interpreted according to the criteria provided in Table 1.

Diffusion Techniques

Quantitative methods that require the measurement of zone diameters tin besides provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size should exist determined using a standardized method^ii,5. This procedure uses paper disks impregnated with 2 mcg of clindamycin to exam the susceptibility of leaner to clindamycin. The deejay diffusion breakpoints are provided in Tabular array 1.

Anaerobic Techniques

For anaerobic bacteria, the susceptibility to clindamycin can be adamant by a standardized test method^2,4. The MIC values obtained should exist interpreted co-ordinate to the criteria provided in Table one.

Table 1: Susceptibility Test Interpretive Criteria for Clindamycin

Pathogen	Susceptibility Interpretive Criteria
	Minimal Inhibitory Concentrations (MIC in mcg/mL)			Disk Improvidence (Zone Diameters in mm)
	Due south	I	R	Southward	I	R
Staphylococcus spp.	≤ 0.5	1-ii	≥ 4	≥ 21	fifteen-xx	≤ 14
Streptococcus pneumoniae and other Streptococcus spp.	≤ 0.25	0.five	≥ 1	≥ 19	sixteen-18	≤ 15
Anaerobic Bacteria	≤ 2	4	≥ eight	NA	NA	NA
NA=non applicable

A study of Susceptible (S ) indicates that the antimicrobial drug is likely to inhibit growth of the pathogen if the antimicrobial drug reaches the concentration usually achievable at the site of infection. A report of Intermediate (I) indicates that the event should be considered equivocal, and, if the microorganism is not fully susceptible to culling, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically full-bodied or in situations where high dosage of drug tin can be used. This category also provides a buffer zone that prevents small, uncontrolled technical factors from causing major discrepancies in interpretation. A report of Resistant (R) indicates that the antimicrobial drug is non likely to inhibit growth of the pathogen if the antimicrobial drug reaches the concentration normally achievable at the infection site; other therapy should be selected.

Quality Control

Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accurateness and precision of the supplies and reagents used in the assay, and the techniques of the individuals performing the test.^2,3,4,five Standard clindamycin pulverisation should provide the MIC ranges in Tabular array 2. For the disk diffusion technique using the ii mcg clindamycin disk the criteria provided in Tabular array 2 should be accomplished.

Table two: Acceptable Quality Control Ranges for Clindamycin

QC Strain	Acceptable Quality Control Ranges
	Minimum Inhibitory Concentration Range (mcg/mL)	Disk Diffusion Range (Zone Diameters in mm)
Enterococcus faecalis1 ATCC 29212	iv-16	NA
Staphylococcus aureus ATCC 29213	0.06-0.25	NA
Staphylococcus aureus ATCC 25923	NA	24-30
Streptococcus pneumoniae ATCC 49619	0.03-0.12	19-25
Bacteroides fragilis ATCC 25285	0.5-2	NA
Bacteroides thetaiotaomicron ATCC 29741	2-8	NA
Clostridium difficiletwo ATCC 700057	ii-8	NA
Eggerthella lenta ATCC 43055	0.06-0.25	NA
1Enterococcus faecalis has been included in this table for quality control purposes only. 2Quality control for C. difficile is performed using the agar dilution method but, all other obligate anaerobes may be tested by either broth microdilution or agar dilution methods. NA=Not applicative ATCC® is a registered trademark of the American Type Culture Collection

REFERENCES

1. Smith RB, Phillips JP: Evaluation of CLEOCIN HCl and CLEOCIN Phosphate in an Aged Population. Upjohn TR 8147-82-9122-021, December 1982.

2. CLSI. Operation Standards for Antimicrobial Susceptibility Testing: 26^th ed. CLSI supplement M100S. Wayne, PA: Clinical and Laboratory Standards Establish; 2016.

3. CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard â€" 10th Edition. CLSI document M07-A10. Wayne, PA: Clinical and Laboratory Standards Institute; 2015.

iv. CLSI. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard-Eighth Edition. CLSI document M11-A8. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.

five. CLSI. Performance Standards for Antimicrobial Disk Susceptibility Tests; Canonical Standard -Twelfth Edition. CLSI document M02-A12. Wayne, PA: Clinical and Laboratory Standards Institute; 2015.

PATIENT Data

Patients should be counseled that antibacterial drugs, including CLEOCIN HCl, should only be used to treat bacterial infections. They exercise not treat viral infections (e.one thousand., the common cold). When CLEOCIN HCl is prescribed to treat a bacterial infection, patients should be told that although it is common to feel ameliorate early on in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full form of therapy may

1. decrease the effectiveness of the firsthand treatment and
2. increment the likelihood that bacteria will develop resistance and will not exist treatable by CLEOCIN HCl or other antibacterial drugs in the future.

• Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued.
• Sometimes after starting treatment with antibiotics, patients tin can develop watery and encarmine stools (with or without breadbasket cramps and fever) fifty-fifty as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their md equally soon equally possible.

From

Report Problems to the Nutrient and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call i-800-FDA-1088.

gylescrist2001.blogspot.com

Source: https://www.rxlist.com/clindamycin-drug.htm

Share :